Please assess the completion status of the following clinical trial:

Trial Title: Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven malignant pleural mesothelioma MPM that is considered resectable according to the following criteria:~   * Confined to one pleural space~  * No chest wall invasion~  * No transdiaphragmatic involvement~  * No invasion of mediastinal structures~2. Age ≥ 18 years~3. Eastern Cooperative Oncology Group performance status 0-1 (Appendix A)~4. Adequate cardiopulmonary reserve defined as follows as assessed within 4 months of study entry:~   * Predicted postoperative forced expiratory volume FEV1 \> 1L~  * Normal left ventricular function (Ejection Fraction EF ≥ 45%) and right ventricular function~  * No pulmonary hypertension noted on preoperative transthoracic echocardiography~5. Must have adequate hematologic, renal and hepatic function as defined by the following laboratory values (completed within 60 days of surgery) Hematologic: Hemoglobin ≥ 9.0 g/dL, absolute neutrophil count (ANC) ≥ 1500/mm3, platelet count ≥ 100,000/mm Renal: Calculated creatinine clearance ≥ 60 mL/min~   The creatinine clearance CrCl is determined by the Cockcroft-Gault formula:~   Males:~   Creatinine Clearance CrCl (mL)/min) = weight (kg) x (140-age) 72 x serum creatinine (mg/dL)~   Females:~   Creatinine Clearance CrCl (mL)/min) = weight (kg) x (140-age) x 0.85 72 x serum creatinine (mg/dL)~   Hepatic: Total bilirubin \< 1.5 times the upper limit of institutional normal value; Aspartate aminotransferase AST (Serum glutamic oxaloacetic transaminase SGOT) and alanine aminotransferase ALT (Serum glutamic pyruvic transaminase SGPT) \< 3 times the upper limit of the institutional normal Coagulation: international normalized ratio INR ≤ 1.5 in patients not utilizing systemic anticoagulation as part of their medical regimen~6. Women of child bearing potential and sexually active males must use an accepted and effective non-hormonal method of contraception~7. Patients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy~8. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~9. The ability to interrupt non-steroidal anti-inflammatory drugs NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.~10. The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.~Exclusion Criteria:~1. Not pregnant or breastfeeding - the drugs used in this study are Pregnancy Category D (clear evidence of risk in pregnancy). A negative pregnancy test is required within 14 days of registration for pre- or perimenopausal (i.e., last menstrual period within one year of registration) women.~2. Patients with a history of another neoplasm, with the exception of non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small field radiotherapy, within 5 years of registration will be excluded.~3. Patients with uncontrolled cardiovascular disease (a history of hospitalization for acute myocardial infarction, arrhythmia, or congestive heart failure within 3 months prior to registration) will be excluded~4. Registered patients with an active infection or with a fever of ≥ 38.5°C within 24 hours of the first scheduled day of protocol initiation will be excluded until their infection and/or fever resolves.~5. Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.~6. Inability to interrupt use of non-steroidal anti-inflammatory drugs (NSAIDS)~7. Peripheral neuropathy \>/= Grade 2 (Common Terminology Criteria for Adverse Events CTCAE)~8. Systemic chemotherapy within 3 weeks of registration~9. Prior Allergies: History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and pemetrexed~10. Presence of third space fluid which cannot be controlled by drainage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Pemetrexed (300 mg/m2) and Cisplatin (175 mg/m2) (Type: EXPERIMENTAL): Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
- Pemetrexed (400 mg/m2) and Cisplatin (175 mg/m2) (Type: EXPERIMENTAL): Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility